Akèy › Kansè ovè › Ohio › Cleveland
Etid klinik pou Kansè ovè nan Cleveland, OH
30 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Cleveland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Louis Stokes Cleveland VA Medical Center, Cleveland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Case Western Reserve University, Cleveland
- UHHS-Chagrin Highlands Medical Center, Beachwood · 10 mi lwen
- UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor · 22 mi lwen
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University Hospitals Cleveland Medical Center, Cleveland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The Cleveland Clinic Taussig Cancer Center, Cleveland
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- Cleveland Clinic - Oncology Department, Cleveland
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Ap rekriteFaz 2
- University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
Ap rekriteFaz 3
- Research Site, Cleveland
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Ap rekriteEtid obsèvasyon
- Cleveland Clinic, Cleveland
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Ap rekriteFaz 2
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- ak 1 plis
Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Cleveland
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- University Hospitals Cleveland Medical Center, Cleveland
- Fairview Hospital, Cleveland
- Cleveland Clinic, Cleveland
- ak 1 plis
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
- UH Cleveland Medical Center, Cleveland
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Ap rekriteFaz 3
- Cleveland Clinic Foundation, Cleveland
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- Cleveland Clinic, Cleveland
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Ap rekriteFaz 3
- Cleveland Clinic, Cleveland
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Ap rekriteFaz 3
- Cleveland Clinic, Cleveland
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Cleveland Clinic Taussig Cancer Institute, Cleveland
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ap rekrite
- Case Western Reserve University, Cleveland
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- ak 4 plis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Case Western Reserve University, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- ak 3 plis
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- University Hospital - Cleveland Medical Center, Cleveland
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Ap rekriteFaz 3
- The Cleveland Clinic Foundation, Cleveland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- UH Cleveland Medical Center, Cleveland
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Ap rekriteFaz 1/2
- Research site, Cleveland
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Ap rekriteFaz 3
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · 12 mi lwen
- ak 1 plis
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Ap rekriteEtid obsèvasyon
- University Hospitals Seidman Cancer Center, Cleveland
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Cleveland Clinic, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mi lwen
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #7, Cleveland
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Ap rekriteFaz 2
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Etid Kansè ovè nan lòt vil
- Houston, TX89 etid
- New York City, NY69 etid
- Boston, MA61 etid
- Los Angeles, CA50 etid
- Nashville, TN49 etid
- Arlington, VA46 etid
- Philadelphia, PA44 etid
- Columbus, OH39 etid
- St. Louis, MO38 etid
- Chicago, IL36 etid
- San Antonio, TX31 etid
- Pittsburgh, PA30 etid
Lòt etid nan Cleveland
- Kansè Poumon ki pa ti selil43 etid
- Kansè (tout kalite)36 etid
- Kansè nan tete35 etid
- Kansè pwostat34 etid
- Ensifizyans kadyak33 etid
- Kansè Metastatik30 etid
- Kansè poumon26 etid
- Kansè kolorektal24 etid
- Maladi kadyovaskilè22 etid
- Kansè Endomèt20 etid
- Leksemi mieloïd egi20 etid
- Maladi Crohn19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.